GlassScriptPhysician profile
Gina Sevigny
NPI 1245399237
$5,049.56
in general payments reported to CMS, 2019-2025
26 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 75% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $138 · 2021: $1,047 · 2022: $1,222 · 2023: $756 · 2024: $385 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,118 · Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,117.50 |
| Food and Beverage | $1,089.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,467.35 | 2021-2022 | |
| Abbvie INC. | $1,273.01 | 2019-2025 | Skyrizi, Botox |
| Almirall LLC | $301.27 | 2019-2025 | Klisyri, Seysara |
| Janssen Biotech, INC. | $289.08 | 2019-2025 | Tremfya, Stelara, Remicade |
| Sun Pharmaceutical Industries INC. | $257.86 | 2020-2024 | Ilumya |
| Incyte Corporation | $169.30 | 2021-2025 | Opzelura |
| Pfizer INC. | $158.33 | 2019-2023 | |
| Amgen INC. | $137.08 | 2020-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $118.56 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $105.23 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $104.71 | 2019-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $97.67 | 2019-2024 | |
| Leo Pharma INC. | $84.94 | 2019-2022 | |
| Celgene Corporation | $71.02 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.02 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $56.91 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $50.82 | 2022-2023 | |
| Organogenesis INC. | $47.33 | 2025 | Novachor |
| Vyne Pharmaceuticals INC. | $39.19 | 2020-2021 | |
| Biofrontera INC. | $38.08 | 2019 | |
| Mimedx Group, INC. | $27.84 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $25.15 | 2019 | |
| Smith+Nephew, INC. | $23.93 | 2023 | Stravix Pl |
| Merck Sharp & Dohme LLC | $20.90 | 2023 | Keytruda |
| Genentech USA, INC. | $14.57 | 2019 | |
| Strata Skin Sciences, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Sevigny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.